Apotex may be able to convince a federal judge to allow it to keep selling the generic version of Bristol-Myers Squibb (BMS) and sanofi-aventis’ lucrative blood-thinner Plavix pending the outcome of the patent trial, but successfully challenging the patent is another story, according to an analyst from Merrill Lynch.